Huawei, Chinese technology giant, is getting ready to significantly boost manufacturing of its cutting-edge artificial intelligence processors, positioning itself to capture more market share as American rival Nvidia faces regulatory obstacles in the region. According to sources with knowledge of internal plans, Huawei Technologies Co. intends to manufacture approximately 600,000 units of its flagship 910C […]Huawei, Chinese technology giant, is getting ready to significantly boost manufacturing of its cutting-edge artificial intelligence processors, positioning itself to capture more market share as American rival Nvidia faces regulatory obstacles in the region. According to sources with knowledge of internal plans, Huawei Technologies Co. intends to manufacture approximately 600,000 units of its flagship 910C […]

Huawei ramps up chip manufacturing, set to rival Nvidia's market dominance

2025/09/30 01:52
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Huawei, Chinese technology giant, is getting ready to significantly boost manufacturing of its cutting-edge artificial intelligence processors, positioning itself to capture more market share as American rival Nvidia faces regulatory obstacles in the region.

According to sources with knowledge of internal plans, Huawei Technologies Co. intends to manufacture approximately 600,000 units of its flagship 910C Ascend processor in the coming year. This figure represents twice the volume produced during the current year. The company encountered difficulties delivering these products throughout much of 2025 due to American trade restrictions.

The Shenzhen-headquartered firm will increase overall production for its Ascend lineup to as many as 1.6 million dies in 2026, the sources revealed. Dies are the fundamental silicon pieces containing chip circuitry.

Successfully reaching these production goals would mark a significant technical achievement for the company, considered China’s primary hope for reducing dependence on foreign processors that drive the nation’s economy.

The figures indicate that Huawei and its key manufacturing ally, Semiconductor Manufacturing International Corp., have discovered methods to address bottlenecks that previously hampered both its AI operations and Beijing’s technology independence goals. The 2025 and 2026 estimates include dies currently in stock and internal calculations of production failure rates, Bloomberg’s sources noted.

Demand for AI processors remains substantial across China

Companies ranging from Alibaba Group Holding Ltd. to DeepSeek require millions of these chips to build and run AI platforms. Nvidia reportedly sold roughly a million H20 chips during 2024 alone.

Last September, Huawei broke from its usual practice of secrecy by publicly announcing a three-year strategy for challenging Nvidia’s market leadership. Rotating Chairman Eric Xu presented multiple Ascend processors, the 950, 960, and 970 models, scheduled for gradual introduction through 2028. These represent the next generation following the years-old 910 series, which currently generates the bulk of

Huawei spearheads a group of Chinese chip manufacturers rushing to create accelerators while Nvidia remains largely excluded from the market through government restrictions. Beijing has blocked or discouraged domestic companies from purchasing Nvidia products over security worries.

Nvidia co-founder Jensen Huang has attempted to convince Chinese buyers that his products pose no security threat, though it remains uncertain whether this situation will change. During its latest earnings report, the company disclosed zero sales of the H20, a version designed specifically for China, in the most recent quarter. As Cryptopolitan reported earlier, China’s Baidu and Alibaba have also dumped Nvidia for domestically developed chips.

Production challenges remain despite summer progress

While some reports suggest Chinese companies plan to triple overall semiconductor output next year, sources described this goal as unrealistic. Production yields, meaning the percentage of usable chips coming off assembly lines, remain disappointing.

Huawei’s current leading AI processor combines two dies into a single chipset, an advanced packaging technique that theoretically increases power. However, this process presents challenges and partly explains ongoing supply shortages that have allowed competitors like Cambricon Technologies Corp. to fill the gap, sources explained.

Nevertheless, Huawei achieved meaningful output improvements during the summer months, sources added. Recent months have shown evidence of Chinese firms, including Shanghai Micro Electronics Equipment Group Co., making substantial progress in equipment technology.

Huawei now plans to introduce a chip following the 910C, initially called the 910D by industry observers, in late 2026, sources said. The company aims for 100,000 units of this new chipset, featuring a more ambitious design packing four dies into one package. Earlier this month, Huawei announced plans for a late-2026 release of what it calls the 950DT.

Altogether, Huawei will distribute roughly 1.6 million dies across two chip types next year, compared to up to 1 million dies in 2025, sources confirmed. Earlier this year, Huawei informed customers it could sell 200,000 Ascend 910Cs by year’s end, plus about 100,000 units set aside for its own cloud computing division and possibly some government-connected projects.

Sharpen your strategy with mentorship + daily ideas - 30 days free access to our trading program

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

a16z Targets $2 Billion Crypto Fund as Venture Capital Eyes Blockchain Recovery

a16z Targets $2 Billion Crypto Fund as Venture Capital Eyes Blockchain Recovery

Andreessen Horowitz’s crypto division, a16z crypto, is reportedly running $2 billion for its fifth crypto investment fund. This move from a firm is happening when
Share
Thenewscrypto2026/03/05 20:29
ArtGis Finance Partners with MetaXR to Expand its DeFi Offerings in the Metaverse

ArtGis Finance Partners with MetaXR to Expand its DeFi Offerings in the Metaverse

By using this collaboration, ArtGis utilizes MetaXR’s infrastructure to widen access to its assets and enable its customers to interact with the metaverse.
Share
Blockchainreporter2025/09/18 00:07
Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Share
BitcoinEthereumNews2025/09/18 03:11